Tadeusz Wojciech Łapiński

Tadeusz Wojciech Łapiński

Auto-generated profile, based on publicly available information

Tadeusz Wojciech Łapiński

Department of Infectious Diseases and Hepatology, Medical University of Bialystok, Bialystok, Poland

Research Focus & Metrics

Academic Career Length

31Years (1996-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
6 February 2012 in Expert Opinion on Investigational Drugs
Verified
Journal Article
Closed access
Robert FlisiakRobert Flisiak
Robert Flisiak
JJJerzy Jaroszewicz
Jerzy Jaroszewicz
Iwona FlisiakIwona Flisiak
Iwona Flisiak
TŁTadeusz Łapiński
Tadeusz Łapiński
Introduction: There are two classes of anti-hepatitis C virus (HCV) agents currently in development: direct-acting antivirals (DAA) and host-targeting antivirals (HTA). Cyclophilin inhibitor alisporivir (ALV), previously known as Debio-025 is the most advanced HTA in development. Areas covered: Experimental and clinical studies demonstrated that ALV has high genetic barrier and no cross-resistance to DAA. Pharmacokinetic studies showed a profile suitable for once-daily administration. Phase I and II studies confirmed strong HCV suppression and that addition of ALV to pegylated IFNα (PegIFNα) and ribavirin (RBV) can improve their efficacy significantly. ALV was well tolerated and prevalence of the most frequent clinical and laboratory adverse events was similar to PegIFNα/RBV. Hyperbilirubinemia was the only significant adverse event related to ALV, but it was transient, reversible and not associated with hepatotoxicity or cholestasis. Expert opinion: ALV is pangenotypic, with once-daily administration and safe, therefore medication can be easy and flexible. There is still a need of data in difficult-to-treat populations and genetic studies allowing selection of possible non-responders. Registration of ALV for IFN-based treatment is expected within 3 years, but ALV is also a good candidate for IFN-sparing combinations with DAA.

1 October 2017 in European Journal of Gastroenterology & Hepatology
Verified
Journal Article
Open access
JPJoanna Pogorzelska
Joanna Pogorzelska
MŁMagda Łapińska
Magda Łapińska
AKAlicja Kalinowska
Alicja Kalinowska
TŁTadeusz W. Łapiński
Tadeusz W. Łapiński
Robert FlisiakRobert Flisiak
Robert Flisiak
Background and aim: Inflammatory changes in the stomach caused by Helicobacter pylori indirectly and directly affect liver function. Moreover, the bacteria may worsen the course of the liver cirrhosis. The study aimed at evaluating the incidence of H. pylori infection among patients with liver cirrhosis, depending on the etiology and injury stage, scored according to Child–Pugh classification. Stage of esophageal varices and endoscopic inflammatory lesions in the stomach were evaluated, depending on the presence of H. pylori infection. Patients and methods: The study included 147 patients with liver cirrhosis: 42 were infected with hepatitis C virus, 31 were infected with hepatitis B virus, 56 had alcoholic liver cirrhosis, and 18 had primary biliary cirrhosis. Diagnosis of H. pylori infection was performed based on the presence of immunoglobulin G antibodies in serum. Results: H. pylori infection was found in 46.9% of patients. The incidence of H. pylori infection among patients with postinflammatory liver cirrhosis was significantly higher (P=0.001), as compared with patients with alcoholic liver cirrhosis. Ammonia concentration was significantly higher in patients infected with H. pylori, compared with noninfected individuals (129 vs. 112 μmol/l; P=0.002). Incidence of H. pylori infection in patients without esophageal varices was significantly lower compared with patients with esophageal varices (14 vs. 60%; P<0.001). Conclusion: H. pylori infection is significantly more frequent among patients with postinflammatory liver cirrhosis (infected with hepatitis C virus or hepatitis B virus) than in patients with alcoholic liver cirrhosis or primary biliary cirrhosis. H. pylori infection correlates with elevated concentration of blood ammonia and the incidence of esophageal varices.

28 August 2013 in Liver International
Verified
Journal Article
Closed access
PDF file
APAnna Parfieniuk-Kowerda
Anna Parfieniuk-Kowerda
TLTadeusz W. Lapinski
Tadeusz W. Lapinski
MRMagdalena Rogalska
Magdalena Rogalska
MŚMagdalena Świderska
Magdalena Świderska
APAnatol Panasiuk
Anatol Panasiuk
Robert FlisiakRobert Flisiak
Robert Flisiak

13 July 2021 in Vaccines
Verified
Journal Article
Open access
PDF file
Piotr RzymskiPiotr Rzymski
Piotr Rzymski
MPMonika Pazgan-Simon
Monika Pazgan-Simon
KSKrzysztof Simon
Krzysztof Simon
TŁTadeusz Łapiński
Tadeusz Łapiński
Dorota Zarębska-MichalukDorota Zarębska-Michaluk
Dorota Zarębska-Michaluk
Robert FlisiakRobert Flisiak
Robert Flisiak
The clinical trials of the COVID-19 vaccines that are authorized in the European Union have revealed high efficacy in preventing symptomatic infections. However, during vaccination campaigns, some vaccine recipients, including those partially and fully vaccinated, will experience severe COVID-19, requiring hospitalization. This may particularly concern patients with a diminished immune response to the vaccine, as well as non-responders. This work has retrospectively analyzed the 92 cases of patients who were hospitalized between 27 December 2020 and 31 May 2021 in four Polish healthcare units due to COVID-19, and who have previously received the COVID-19 vaccine (54.3% ≤ 14 days after the first dose, 26.1% > 14 days after the first dose, 7.6% ≤ 14 days after the second dose, and 12% > 14 days after the second dose). These patients represented a minute fraction (1.2%) of all the COVID-19 patients who were hospitalized during the same period in the same healthcare institutions. No significant differences in white blood count, absolute lymphocyte count nadir, C-reactive protein, interleukin-6, procalcitonin, oxygen saturation, lung involvement, and fever frequency were found between the recipients of the first and second vaccine dose. A total of 15 deaths were noted (1.1% of all fatal COVID-19 cases in the considered period and healthcare units), including six in patients who received the second dose (five > 14 days after the second dose)—three of these subjects were using immunosuppressive medicines, and two were confirmed to be vaccine non-responders. The study reassures that severe COVID-19 and deaths are not common in vaccinated individuals, highlights that the clinical course in such patients may not reveal any distinctive features, and advocates for close monitoring of those at a higher risk of vaccine failure.

Verified
Journal Article
Open access
PDF file
Robert FlisiakRobert Flisiak
Robert Flisiak
JJJerzy Jaroszewicz
Jerzy Jaroszewicz
MRMagdalena Rogalska
Magdalena Rogalska
TŁTadeusz Łapiński
Tadeusz Łapiński
AKAleksandra Berkan Kawinska
Aleksandra Berkan Kawinska
Dorota Zarębska-MichalukDorota Zarębska-Michaluk
Dorota Zarębska-Michaluk
Despite direct viral effect, the pathogenesis of coronavirus disease 2019 (COVID-19) includes an overproduction of cytokines including interleukin 6 (IL-6). Therefore, tocilizumab (TOC), a monoclonal antibody against IL-6 receptors, was considered as a possible therapeutic option. Patients were selected from the SARSTer database, containing 2332 individuals with COVID-19. Current study included 825 adult patients with moderate to severe course. Analysis was performed in 170 patients treated with TOC and 655 with an alternative medication. The end-points of treatment effectiveness were death rate, need for mechanical ventilation, and clinical improvement. Patients treated with TOC were balanced compared to non-TOC regarding gender, age, BMI, and prevalence of coexisting conditions. Significant effect of TOC on death was demonstrated in patients with baseline IL-6 > 100 pg/mL (hazard ratio [HR]: 0.21, 95% confidence interval [CI]: 0.08–0.57). The best effectiveness of TOC was achieved in patients with a combination of baseline IL-6 > 100 pg/mL and either SpO2 ≤ 90% (HR: 0.07) or requiring oxygen supplementation (HR: 0.18). Tocilizumab administration in COVID-19 reduces mortality and speeds up clinical improvement in patients with a baseline concentration of IL-6 > 100 pg/mL, particularly if they need oxygen supplementation owing to the lower value of SpO2 ≤ 90%.

1 January 2005 in World Journal of Gastroenterology
Verified
Journal Article
Open access
TLTadeusz Wojciech Lapinski
Tadeusz Wojciech Lapinski
AIM: To analyze the effectiveness and safety of lamivudine treatment in patients with chronic HBV infection undergoing hemodialysis or after kidney transplantation, and to study the frequency of tyrosine - methionine - aspartate - aspartate (YMDD) mutation occurrence after lamivudine treatment.